$NKTX
Nkarta Inc

2021 Q2 Form 10-Q Financial Statement

#000156459021044018 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.677M $2.490M
YoY Change 127.99% 137.14%
% of Gross Profit
Research & Development $15.96M $7.862M
YoY Change 102.96% 117.13%
% of Gross Profit
Depreciation & Amortization $400.0K $100.0K
YoY Change 300.0% 0.0%
% of Gross Profit
Operating Expenses $21.63M $10.36M
YoY Change 108.91% 121.6%
Operating Profit -$21.63M -$10.36M
YoY Change 108.91% 121.71%
Interest Expense $104.0K $30.00K
YoY Change 246.67% -117.65%
% of Operating Profit
Other Income/Expense, Net $99.00K -$40.71M
YoY Change -100.24% 24257.85%
Pretax Income -$21.54M -$51.07M
YoY Change -57.83% 955.17%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.54M -$51.07M
YoY Change -57.83% 955.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.66
Diluted Earnings Per Share -$0.66 -$1.678M
COMMON SHARES
Basic Shares Outstanding 32.83M
Diluted Shares Outstanding 32.83M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $279.8M $21.60M
YoY Change 1195.38%
Cash & Equivalents $24.42M $17.75M
Short-Term Investments $255.4M $3.900M
Other Short-Term Assets $4.132M $24.52K
YoY Change 16752.24%
Inventory
Prepaid Expenses $2.420M $337.7K
Receivables
Other Receivables
Total Short-Term Assets $283.9M $22.30M
YoY Change 1173.25%
LONG-TERM ASSETS
Property, Plant & Equipment $11.35M $16.80M
YoY Change -32.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.776M $4.600M
YoY Change -61.39%
Total Long-Term Assets $25.18M $21.30M
YoY Change 18.2%
TOTAL ASSETS
Total Short-Term Assets $283.9M $22.30M
Total Long-Term Assets $25.18M $21.30M
Total Assets $309.1M $43.60M
YoY Change 608.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.161M $1.700M
YoY Change 27.12%
Accrued Expenses $7.162M $5.300M
YoY Change 35.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.26M $59.74M
YoY Change -82.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.47M $120.0K
YoY Change 8630.19%
Total Long-Term Liabilities $10.47M $120.0K
YoY Change 8630.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.26M $59.74M
Total Long-Term Liabilities $10.47M $120.0K
Total Liabilities $20.73M $67.69M
YoY Change -69.38%
SHAREHOLDERS EQUITY
Retained Earnings -$158.9M -$86.43M
YoY Change 83.85%
Common Stock $2.541M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $288.4M -$83.89M
YoY Change
Total Liabilities & Shareholders Equity $309.1M $43.62M
YoY Change 608.71%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$21.54M -$51.07M
YoY Change -57.83% 955.5%
Depreciation, Depletion And Amortization $400.0K $100.0K
YoY Change 300.0% 0.0%
Cash From Operating Activities -$17.45M -$10.24M
YoY Change 70.4% 214.11%
INVESTING ACTIVITIES
Capital Expenditures -$1.381M -$2.480M
YoY Change -44.31% -1018.52%
Acquisitions
YoY Change
Other Investing Activities -$19.57M $5.300M
YoY Change -469.32%
Cash From Investing Activities -$20.96M $2.810M
YoY Change -845.73% -1140.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 252.0K 8.810M
YoY Change -97.14% 46.35%
NET CHANGE
Cash From Operating Activities -17.45M -10.24M
Cash From Investing Activities -20.96M 2.810M
Cash From Financing Activities 252.0K 8.810M
Net Change In Cash -38.15M 1.380M
YoY Change -2864.64% -44.58%
FREE CASH FLOW
Cash From Operating Activities -$17.45M -$10.24M
Capital Expenditures -$1.381M -$2.480M
Free Cash Flow -$16.07M -$7.760M
YoY Change 107.06% 119.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5677000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
21634000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21634000
CY2020Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-40741000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
104000
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
27000
us-gaap Investment Income Net
InvestmentIncomeNet
214000
us-gaap Investment Income Net
InvestmentIncomeNet
152000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
99000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-40710000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
206000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-40007000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-21535000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-51065000
us-gaap Net Income Loss
NetIncomeLoss
-40908000
us-gaap Net Income Loss
NetIncomeLoss
-59771000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-28000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-21535000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
368000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
321220000
CY2021Q1 nktx Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
9000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
756000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3347000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
31000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-19373000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
305990000
CY2021Q2 nktx Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
9000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
256000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3690000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-21535000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
288382000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-25482000
CY2020Q1 nktx Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
14000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
482000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8706000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-33692000
CY2020Q2 nktx Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
12000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
285000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
566000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-51065000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-83890000
us-gaap Profit Loss
ProfitLoss
-40908000
us-gaap Profit Loss
ProfitLoss
-59771000
us-gaap Share Based Compensation
ShareBasedCompensation
7037000
us-gaap Share Based Compensation
ShareBasedCompensation
1048000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
667000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
281000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1576000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
32000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
231000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
178000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-40163000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
987000
nktx Increase Decrease In Accounts Payable And Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities
285000
nktx Increase Decrease In Accounts Payable And Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities
-27000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32099000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18528000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2411000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4812000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
86234000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
3577000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
47500000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
16100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41145000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
10245000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1012000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
287000
nktx Proceeds From Early Exercise Of Stock Options
ProceedsFromEarlyExerciseOfStockOptions
12000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7711000
nktx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
2440000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2713000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97105000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20875000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24873000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18162000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24421000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17749000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
452000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1012000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8104000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-72232000
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
413000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24873000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18162000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158900000
CY2021Q2 nktx Cash Cash Equivalents Restricted Cash And Short Term Investments
CashCashEquivalentsRestrictedCashAndShortTermInvestments
280300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to preclinical studies, fair value of assets and liabilities, share-based compensation and income taxes. Management bases its estimates on historical experience, knowledge of current events and actions it may undertake in the future that management believes to be reasonable under the circumstances. Actual results may differ from these estimates and assumptions.</p>
CY2021Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
21331000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-21535000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-51065000
us-gaap Net Income Loss
NetIncomeLoss
-40908000
us-gaap Net Income Loss
NetIncomeLoss
-59771000
CY2021Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
32879406
CY2020Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1815833
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
32843343
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1775961
CY2021Q2 nktx Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
52041
CY2020Q2 nktx Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
117273
nktx Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
59613
nktx Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
121657
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32827365
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1698560
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32783730
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1654304
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-30.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-36.13
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4340291
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9923669
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
255382000
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
276713000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3534000
CY2021Q2 nktx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1297000
CY2020 nktx Impairments
Impairments
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2420000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2586000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1336000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4132000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3922000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13448000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10781000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2098000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1431000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11350000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9350000
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2021Q2 nktx Accrued Property And Equipment Liabilities Current
AccruedPropertyAndEquipmentLiabilitiesCurrent
156000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5808000
CY2020Q4 nktx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1675000
CY2020Q4 nktx Accrued Property And Equipment Liabilities Current
AccruedPropertyAndEquipmentLiabilitiesCurrent
117000
CY2021Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
933000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
927000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
us-gaap Operating Lease Payments
OperatingLeasePayments
1000000.0
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1201000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2288000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2285000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2184000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2200000
CY2021Q2 nktx Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
7322000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17480000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4785000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12695000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2287000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10408000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12695000
CY2021Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2020Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3640715
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
862847
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
48.74
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
194354
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15766
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
18.31
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4293442
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.82
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1079227
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.15
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4293442
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
33.04
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3690000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
566000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7037000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1048000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
43500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M19D
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-21-044018-index-headers.html Edgar Link pending
0001564590-21-044018-index.html Edgar Link pending
0001564590-21-044018.txt Edgar Link pending
0001564590-21-044018-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nktx-10q_20210630.htm Edgar Link pending
nktx-10q_20210630_htm.xml Edgar Link completed
nktx-20210630.xsd Edgar Link pending
nktx-20210630_cal.xml Edgar Link unprocessable
nktx-20210630_def.xml Edgar Link unprocessable
nktx-20210630_lab.xml Edgar Link unprocessable
nktx-20210630_pre.xml Edgar Link unprocessable
nktx-ex101_6.htm Edgar Link pending
nktx-ex311_12.htm Edgar Link pending
nktx-ex312_11.htm Edgar Link pending
nktx-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending